Drug intelligence / Profile preview

CTH-001

Development stage: Unknown
Lead developer: Cartherics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**CTH-001** is an investigational autologous CAR-T cell therapy developed by Cartherics in collaboration with Peter MacCallum Cancer Centre for the treatment of cutaneous T-cell lymphoma (CTCL) and ovarian cancer. It targets refractory CTCL patients, with a planned phase 1 clinical trial enrolling six patients to primarily assess safety. Preclinical data support its advancement into clinical evaluation for these hematologic and solid tumor indications.[8][10]

Targets

TAG-72

Beyond the preview

Go deeper on CTH-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH-001.

Explore the full profile